Lunesta causes cancer.
January 1
Public Citizen, a watchdog consumer group, has expressed concern about possible cancer risks with the newly approved sleeping pill, Lunesta (eszopiclone).
This is based on findings of tumors in lab animals and DNA damage in early studies. There were also some isolated reports of breast and skin cancers in human clinical trials with Lunesta.
The FDA looked at this data before approval of Lunesta...and concluded that there's no proof of a cancer risk. They say the incidence of cancer with Lunesta ISN'T any higher than what's expected in the general population.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote